Dimensional Fund Advisors LP Purchases 196,981 Shares of Kenvue Inc. $KVUE

Dimensional Fund Advisors LP grew its holdings in Kenvue Inc. (NYSE:KVUE) by 0.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,270,175 shares of the company’s stock after purchasing an additional 196,981 shares during the period. Dimensional Fund Advisors LP’s holdings in Kenvue were worth $383,938,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in KVUE. Oak Thistle LLC purchased a new stake in Kenvue during the fourth quarter valued at $1,563,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Kenvue by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock worth $7,088,000 after acquiring an additional 84,219 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Kenvue by 3,889.9% in the fourth quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock worth $53,056,000 after purchasing an additional 2,998,635 shares in the last quarter. Cohen Capital Management Inc. purchased a new stake in Kenvue in the 4th quarter worth $2,448,000. Finally, State of Wyoming raised its stake in Kenvue by 233.5% during the 4th quarter. State of Wyoming now owns 97,992 shares of the company’s stock valued at $1,690,000 after purchasing an additional 68,609 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.59% of the company’s stock.

Kenvue Stock Performance

Shares of Kenvue stock opened at $18.98 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The company has a market capitalization of $36.43 billion, a PE ratio of 22.32, a P/E/G ratio of 1.44 and a beta of 0.47. The company has a 50-day simple moving average of $18.26 and a two-hundred day simple moving average of $17.88. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter in the prior year, the company posted $0.24 earnings per share. Kenvue’s revenue for the quarter was up 4.5% compared to the same quarter last year. Research analysts expect that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio is 97.65%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. Wall Street Zen raised Kenvue to a “buy” rating in a research report on Sunday, July 12th. Citigroup reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Barclays raised their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.